Print Page    E-mail Page    RSS    E-mail Alerts 

2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013
Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the first patient has been randomized into a Phase 2b study evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).  The first patient was treated at The Lung Research Center in Chesterfield, MO, by Neil A. Ettinger, M.D. The iNO-PF Phase 2b, randomized, double-blind, placebo-cont...